BY CHRISTOPHER DUE KARLSSON
-
Analyst points to several reasons for Novo’s silence over next steps for weight-loss tablet
The pharmaceutical firm’s diabetes mellitus medicine company might contribute, according to Sydbank elderly expert Søren Løntoft Hansen.
-
Analyst points to several reasons for Novo’s silence over next steps for weight-loss tablet
The pharmaceutical company’s diabetes drug business may play a role, according to Sydbank senior analyst Søren Løntoft Hansen.
-
Analyst points to several reasons for Novo’s silence over next steps for weight-loss tablet
The pharmaceutical company’s diabetes drug business may play a role, according to Sydbank senior analyst Søren Løntoft Hansen.
-
GN Group CEO buys almost 20,000 shares in own firm
In total amount, Peter Karlströmer has actually gotten 18,750 GN Team shares at a typical rate of DKK 153.60 per share.
-
Norwegian Refugee Council leverages Okta for Good cyber scheme
Norwegian Evacuee Council leverages Okta forever cyber systemRead More
-
Novo Nordisk waives commenting on possible retaliation for Eli Lilly price initiative
Rather, the Danish pharmaceutical huge describes the magazine of the business’s following quarterly record, where, according to journalism division, it will certainly be feas…
-
Leo Pharma CEO is fully confident about strategy despite failed phase III trial
The ongoing self-confidence in the technique is not the very least because of the dermatology business’s medication prospect delgocitinib, states president Christophe Bourdon…
-
GN’s hearing aid business meets upper end of own forecast: CFO declines to comment on upward adjustment
Søren Jelert, CFO at GN, worries that the business was consulted with uncertainty when the overview for business leg was originally introduced.
-
Leo Pharma’s newly acquired candidate fails phase III trial
In keeping with Leo Pharma, the outcomes do thus not help an utility to the US well being authorities, FDA.
-
Bavarian Nordic to present financial result: Mpox outbreak steals thunder from travel vaccines
In spite of a solid concentrate on mpox, Sydbank anticipates Bavarian Nordic to duplicate the 2024 projection in Thursday’s record.
